Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 15/20 | 0.56 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.56 |
| ▸ | BRD4 | O60885 | 7/20 | 0.49 |
| ▸ | BPTF | Q12830 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23815730 | 0.87 | KAT2B (0.51) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL23682833 | 0.78 | KAT2B (0.50) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL27536539 | 0.71 | KAT2B (0.65) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL7160804 | 0.70 | KAT2B (0.74) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL23682831 | 0.66 | BPTF (1.00) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL3247038 | 0.66 | KAT2B (0.65) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL12160455 | 0.66 | KAT2B (0.56) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL979278 | 0.65 | KAT2B (0.60) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL9982691 | 0.65 | KDM4E (0.64) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL26910156 | 0.64 | BPTF (1.00) | KAT2BBRD9BRD4BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KAT2B 36/4885BRD9 2265/4885BRD4 983/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KAT2B 645/4885BRD9 4029/4885BRD4 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.